I'd have to stick with my original $2.97 as I thought we'd have data by end of q1 as had been suggested.
Will be interesting to see how they present the data as looking back at original animal trials they were talking about comparing against soframycin and achieving 39% reduction in bacterial count comparet to 29%. How that relates to actual wound healing in humans will be interesting. May not be as clear cut as the resent sinusitis case that was healed. By the same token if the market is aware of what they are trying to do or if they explain it well then even "as good as" current standard of care should be huge news when we factor in the non resistance building side of things.
RCE Price at posting:
$1.11 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)